573 related articles for article (PubMed ID: 26056165)
1. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
Mamonkin M; Rouce RH; Tashiro H; Brenner MK
Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
[TBL] [Abstract][Full Text] [Related]
2. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
[TBL] [Abstract][Full Text] [Related]
3. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
[TBL] [Abstract][Full Text] [Related]
4. Engineered T cells can fight malignant T cells.
Stauss HJ
Blood; 2015 Aug; 126(8):927-8. PubMed ID: 26294714
[TBL] [Abstract][Full Text] [Related]
5. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
6. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
7. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
[TBL] [Abstract][Full Text] [Related]
9. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
10. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
11. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
12. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
13. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
Fang KK; Lee J; Khatri I; Na Y; Zhang L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
[TBL] [Abstract][Full Text] [Related]
15. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L; Sun M; Wang Z
Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
[TBL] [Abstract][Full Text] [Related]
17. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
19. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
[TBL] [Abstract][Full Text] [Related]
20. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]